nucleic acids (PNAs) hybridize to natural oligonucleotides according to Watson and Crick base-pairing rules. The robustness of PNA oligomers and ease of synthesis have made them an attractive platform to encode small or macromolecules for microarraying purposes and other applications based on programmable self assembly. A cornerstone of these endeavors is the orthogonality of PNAsynthesis with other chemistries
Optimized Synthesis of Fmoc/Boc‐Protected PNA Monomers and their Assembly into PNA Oligomers.
作者:Ashif Y. Shaikh、Fredrik Björkling、Peter E. Nielsen、Henrik Franzyk
DOI:10.1002/ejoc.202100278
日期:2021.5.20
Fmoc/Boc-protected PNAmonomers were efficiently synthesized on a multigram scale and proved compatible with PNA oligomer synthesis by using manual and automated protocols. Screening of coupling conditions included isolation of byproducts and determination of purity by analytical HPLC and MALDI-TOF mass spectrometry; this revealed phosphonium salts as superior coupling reagents for assembly of PNA.
Expanding the scope of PNA-encoded libraries: divergent synthesis of libraries targeting cysteine, serine and metallo-proteases as well as tyrosine phosphatases
作者:François Debaene、Julien A. Da Silva、Zbigniew Pianowski、Fernando J. Duran、Nicolas Winssinger
DOI:10.1016/j.tet.2007.03.033
日期:2007.7
Seven PNA-encoded combinatorial libraries targeting proteases and phosphatases with covalent reversible and irreversible mechanism-based inhibitors were prepared. The libraries were synthesized using modified PNA monomers, which dramatically increase the water solubility of the libraries in biologically relevant buffers. The libraries were shown to selectively inhibit targeted enzymes. (c) 2007 Elsevier Ltd. All rights reserved.
[EN] OLIGONUCLEOTIDE ANALOGUE MODULATORS OF ONCOGENES<br/>[FR] MODULATEURS D'ONCOGÈNES ANALOGUES D'OLIGONUCLÉOTIDES
申请人:[en]NEUBASE THERAPEUTICS, INC.
公开号:WO2022261030A1
公开(公告)日:2022-12-15
The present disclosure relates to compounds and methods of modulating target nucleic acids that contain single nucleotide polymorphisms such as KRAS codon 12 mutations. Compounds disclosed herein can preferentially bind a sequence of nucleic acids encoding for a mutant Ras protein, thereby selectively modulating expression of the mutant protein.